Navigation Links
Experimental Vaginal Gel Doesn't Ward Off HIV
Date:12/4/2008

South African women using Carraguard had no decrease in infections, trial found

THURSDAY, Dec. 4 (HealthDay News) -- A microbicidal vaginal gel called Carraguard doesn't protect women from HIV infection.

That's the conclusion of a study that included more than 6,200 sexually-active, HIV-negative women at three sites in South Africa.

The women were given either Carraguard or a placebo gel and told to use one applicator of gel and a condom each time they had vaginal sex. The women, who were followed for up to two years, visited a clinic every three months to have tests for HIV infection and pregnancy, pelvic examinations, risk reduction counseling, and treatment for curable sexually transmitted diseases and vaginal infections.

The rate of HIV infection among women using Carraguard was 3.3 per 100-woman years, compared with 3.8 per 100-woman years in the placebo group. Rates of self-reported gel use were similar in both groups (96.2 percent Carraguard, 95.9 percent placebo), but applicator testing indicated that actual gel use was much lower (41.1 percent Carraguard, 43.1 percent placebo). Self-reported condom use was 64.1 percent for both groups.

The findings were published in this week's issue of The Lancet.

"This study did not show Carraguard's efficacy in prevention of male-to-female transmission of HIV, although no safety concerns were recorded. Low levels of gel use could have compromised the potential to detect a significant protective effect. Although the results from this and other completed microbicide efficacy trials have been disappointing, the search for female-controlled HIV-prevention methods must continue," wrote researchers from the Population Council in New York City and their colleagues.

Carraguard, a carrageenan-based compound, was developed by the Population Council.

In an accompanying comment, Dr. Willard Cates and Dr. Paul Feldblum, of Family Health International in North Carolina, wrote that no single method of HIV prevention will be adequate.

"Rather a combination of partly effective prevention approaches will be bundled into packages targeted to specific populations. This bundling will involve behavioral, biomedical, and structural interventions, each designed to reinforce the effect of the other. The cumulative influence of combination prevention is our hope for thwarting the spread of HIV," they said.

More information

The U.S. Centers for Disease Control and Prevention has more about HIV infection risk factors and prevention.



-- Robert Preidt



SOURCE: The Lancet, news release, Dec. 5, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
2. Experimental Antidepressants Offer Faster Relief
3. Experimental drug shows promise in advanced kidney cancer
4. Experimental drug boosts survival in recurrent ovarian cancer
5. Experimental cancer pharmaceuticals under trial
6. Experimental Drug Fails Against Heart Failure
7. Experimental Drug Fights Prostate Cancer
8. Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
9. Experimental Vaccine Halts Prostate Cancer in Mice
10. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
11. 52 minority scientists receive travel fellowships to Experimental Biology 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Vaginal Gel Doesn't Ward Off HIV
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, a family ... and Raleigh regions, is organizing an extended charity drive to benefit the family ... abnormality. , After struggling since birth with several health challenges, T.J. was later ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... While it’s ... poses a problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , ... medication in darkness or restricted lighting. As such, it eliminates the need to turn ...
(Date:10/13/2017)... , ... October 13, 2017 , ... PurhealthRX , ... Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize ... providing a CBD form that can be easily incorporated into liquid products, while reducing ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton ... staged a mock evacuation of the facility as part of a disaster drill on ... Echo Hose EMS and Shelton City Emergency Manager, as well as the Connecticut ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
Breaking Medicine Technology: